IPO registrations (S-1, F-1) · Registrants
Pelthos Therapeutics Inc.
- SEC CIK
- 1919246 · filings on EDGAR ↗
- Name on the registration
- Chromocell Therapeutics Corp
- Former names
- Channel Therapeutics Corp (2024–2025); Chromocell Therapeutics Corp (2022–2024)
- Registration
- Form S-1, first filed 2023-01-11, last 2024-07-29; 2 initial registrations, 13 amendments
- Outcome
- Final prospectus filed 2024-02-20; declared effective 2024-02-14
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- NV
- Business address
- 4020 STIRRUP CREEK DRIVE, SUITE 110, Durham, NC 27703
- EIN
- 86-3335449
- Ticker
- PTHS (NYSE)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Pelthos Therapeutics Inc. on the corporate pages
Offering terms
- Proposed price range
- $5.50–$6.50 per share (S-1/A filed 2024-02-14)
- Final price
- $6.00 per share, within the range (424B4 filed 2024-02-20, an initial public offering)
- Shares sold
- 1,100,000
- Gross proceeds
- $6,600,000 before underwriting discounts and any over-allotment option
- Listing
- NYSE American under the symbol CHRO
- Lead underwriters
- A.G.P./Alliance Global Partners
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Form D issuer: Pelthos Therapeutics Inc. EXACT (CIK (EXACT))
- SEC filer: Channel Therapeutics Corp EXACT (CIK (EXACT))
Filings 23
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2023-01-11 | S-1 | S-1 (registration) | Chromocell Therapeutics Corp | 0001753926-23-000040 ↗ |
| 2023-01-20 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-000067 ↗ |
| 2023-05-01 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-000555 ↗ |
| 2023-06-30 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-000873 ↗ |
| 2023-07-20 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-000939 ↗ |
| 2023-09-01 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-001178 ↗ |
| 2023-10-16 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-001338 ↗ |
| 2023-10-25 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-001385 ↗ |
| 2023-11-08 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-23-001439 ↗ |
| 2024-01-16 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-24-000105 ↗ |
| 2024-01-30 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-24-000182 ↗ |
| 2024-02-07 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-24-000232 ↗ |
| 2024-02-12 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-24-000266 ↗ |
| 2024-02-14 | S-1/A | S-1/A (amendment) | Chromocell Therapeutics Corp | 0001753926-24-000293 ↗ |
| 2024-02-14 | EFFECT | EFFECT (declared effective) | Chromocell Therapeutics Corp | 9999999995-24-000442 ↗ |
| 2024-02-20 | 424B4 | 424B4 (final prospectus) | Chromocell Therapeutics Corp | 0001753926-24-000342 ↗ |
| 2024-02-20 | 424B4 | 424B4 (final prospectus) | Chromocell Therapeutics Corp | 0001753926-24-000343 ↗ |
| 2024-07-29 | S-1 | S-1 (registration) | Chromocell Therapeutics Corp | 0001753926-24-001279 ↗ |
| 2024-08-06 | EFFECT | EFFECT (declared effective) | Chromocell Therapeutics Corp | 9999999995-24-002442 ↗ |
| 2024-12-02 | EFFECT | EFFECT (declared effective) | Channel Therapeutics Corp | 9999999995-24-003629 ↗ |
| 2024-12-19 | EFFECT | EFFECT (declared effective) | Channel Therapeutics Corp | 9999999995-24-003826 ↗ |
| 2025-09-24 | EFFECT | EFFECT (declared effective) | Pelthos Therapeutics Inc. | 9999999995-25-003079 ↗ |
| 2026-02-09 | EFFECT | EFFECT (declared effective) | Pelthos Therapeutics Inc. | 9999999995-26-000493 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-14 | S-1/A | registration statement | $5.50–$6.50 | 1,039,657 | - | NYSE American CHRO | 2 | primary document; range, shares headline, cover names 2 | document ↗ | |
| 2024-02-20 | 424B4 | final prospectus | $6.00 | 1,100,000 | $6,600,000 | NYSE American CHRO | 1 | primary document; price sentence, shares headline, proceeds table, cover names 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AME Equities LLC | TenPercentOwner | 1 | 2024 | ||
| Aperture Healthcare Ventures Ltd. | TenPercentOwner | 1 | 2024 | ||
| Balmoral Financial Group LLC | TenPercentOwner | 1 | 2024 | ||
| Boswell Prayer Ltd. | TenPercentOwner | 1 | 2024 | ||
| Davis Todd C | Director; Director,TenPercentOwner | 8 | 2024–2026 | ||
| Francis Knuettel II | Officer | CEO, Pres., CFO Treas & Secty; CEO, Pres., CFO, Treas & Secty; CFO, Treas & Secty; Chief Financial Officer; Interim CEO, CFO, Treas & Sec; Interim CEO, CFO Treas & Secty | 13 | 2024–2026 | |
| Friedberg Ezra M | Director; Director,TenPercentOwner | 13 | 2024–2026 | ||
| Lang Eric | Officer | Chief Medical Officer | 2 | 2024 | |
| Malamut Richard | Director | 7 | 2024–2026 | ||
| Motif Pharmaceuticals Ltd. | TenPercentOwner | 1 | 2024 | ||
| Simmons Chia-Lin | Director | 3 | 2024–2025 | ||
| LIGAND PHARMACEUTICALS INC | Director,TenPercentOwner; TenPercentOwner | 4 | 2025 | ||
| Baxter Richard B | Director | 3 | 2025–2026 | ||
| Greenleaf Peter | Director | 5 | 2025–2026 | ||
| Pauls Matthew | Director | 6 | 2025–2026 | ||
| Rangarao Sai | Officer | Chief Commercial Officer | 3 | 2025–2026 | |
| Plesha Scott M. | Director,Officer | CEO and President | 3 | 2025–2026 | |
| Einhorn Andrew J. | Director | 2 | 2025 | ||
| GAY JOHN M. | Officer | Chief Financial Officer | 1 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2025-11-19 | Pelthos Therapeutics Inc. | Pharmaceuticals | $18,000,000 | $18,000,000 | 8 | 1 |
| 2025-07-10 | Pelthos Therapeutics Inc. | Pharmaceuticals | $50,100,000 | $50,100,000 | 13 | 1 |
| 2024-08-06 | Chromocell Therapeutics Corp | Pharmaceuticals | $30,000,000 | $0 | 1 | 1 |
| 2024-08-06 | Chromocell Therapeutics Corp | Pharmaceuticals | $750,000 | $750,000 | 1 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Pelthos Therapeutics Inc. | NC | Form D private offerings | CIK (EXACT) |
| SEC filer | Pelthos Therapeutics Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Pelthos Therapeutics Inc. | NC | Trademarks (USPTO) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), NC first:
- ALDAGEN INC NC
- FENNEC PHARMACEUTICALS INC. NC
- TENGION INC NC
- Chelsea Therapeutics International, Ltd. NC
- AERIE PHARMACEUTICALS INC NC
- PRECISION BIOSCIENCES INC NC
- Axium Pharmaceuticals Inc. NC
- Immunovant, Inc. NC
- Humacyte, Inc. NC
- PROKIDNEY CORP. NC
In other datasets, the same topic (Health) in NC:
- Nonprofit: 24 FOUNDATION INC (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health